Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned an average recommendation of “Moderate Buy” from the twenty-four analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $298.09.

ALNY has been the subject of a number of research reports. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Piper Sandler reiterated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Scotiabank raised their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Finally, Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th.

Alnylam Pharmaceuticals Stock Up 1.1 %

Shares of ALNY opened at $246.58 on Wednesday. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company’s fifty day moving average is $266.55 and its two-hundred day moving average is $250.23. The firm has a market cap of $31.80 billion, a PE ratio of -94.11 and a beta of 0.32. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.15 EPS. Analysts forecast that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the transaction, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This represents a 10.04 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,122 shares of company stock valued at $2,540,455. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Diversified Trust Co acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $1,210,000. Los Angeles Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares during the period. Breakwater Capital Group bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $249,000. Sanctuary Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $578,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 22.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock worth $20,165,000 after purchasing an additional 13,422 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.